<DOC>
	<DOCNO>NCT00655330</DOCNO>
	<brief_summary>This prospective randomized control , open-labeled study identify efficacy probucol combination valsartan patient Diabetes nephropathy . The reduction urinary albumin proteinuria primary outcome study . The expected study duration 48 week .</brief_summary>
	<brief_title>Probucol Combined With Valsartan Reducing Proteinuria Diabetes Nephropathy</brief_title>
	<detailed_description>prospective randomize control , open-labeled study patient Diabetes nephropathy - Arm 1 : Valsartan + Probucol Valsartan ( 160mg/day ) + Probucol ( 750mg/day ) - Arm 2 : Valsartan + Placebo Valsartan ( 160mg/day ) + Placebo</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Type 2 Diabetes nephropathy Urinary albumin excretion 13g/24hours Serum creatinine &lt; 3mg/dl Type 1 diabetes mellitus Renal disease type 2 Diabetes nephropathy Renal artery stenosis Severe heart diseases Tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>valsartan</keyword>
	<keyword>probucol</keyword>
	<keyword>Proteinuria</keyword>
</DOC>